FDA approves ‘life-altering’ pancreatic cancer drug that nearly doubles life expectancy

The US Food and Drug Administration announced today that it has approved a groundbreaking new treatment option for pancreatic cancer. Manufactured by Revolution Medicines, daraxonrasib made headlines earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug — which left his skin bloody and “bubbling” but is also giving him more time with his family amid his battled with Stage 4 pancreatic cancer.